Introduction: Sinonasal squamous cell carcinoma (SCC) accounts for Ͻ1% of all malignancies but represents 70% of sinonasal cancer. Up to 10% of SCCs are associated with inverted papilloma (IPSCC). Studies that compare patients, treatment, and outcomes of SCC and IPSCC are absent in the literature.
S inonasal malignancies account for Ͻ1% of all human cancers. 1 Of these paranasal cancers, squamous cell carcinoma (SCC) accounts for between 60 and 75%. 1 Prognosis tends to be poor, often due to advanced stage at diagnosis and proximity to the orbit and skull base. 2 Sinonasal SCC has been related to industrial exposure, including nickel and welding fumes, with some recent subgroup analyses that demonstrated a link to human papilloma virus (HPV). 3 SCC can also arise from an existing inverted papilloma (IP). Also known as schneiderian papillomas, IPs tend to be rare, comprising up to 4% of all nasal tumors. 4 Although pathologically benign, these tumors have three distinguishing characteristics: local aggression, high recurrence, and association with carcinoma, with rates of malignant transformation that approach 10%. 5, 6 Epstein-Barr virus was thought to be a causative factor; however, recent evidence disputes this. 7 There also has been interest in a correlation between HPV and IP; however, the most recent evidence is contradictory. [7] [8] [9] [10] Diagnosis typically involves tissue biopsy; however, there has been some recent interest in the use of SCC antigen as a differentiating factor from inflammatory disease. 11 Treatment is typically surgical, with low recurrence rates with a purely endoscopic approach. 12 SCC can form synchronously or metachronously from IP, with a significant proportion being the former. 13 Factors that precipitate malignant transformation are unclear; however, once an SCC associated with an IP (IPSCC) is identified, contemporary management paradigms suggest that the treatment strategy parallels that for sinonasal SCC. This typically consists of surgical resection, followed by adjuvant radiation, except in T1 mucosal disease in which surgical therapy alone can be definitive. 14 In recurrent disease, chemotherapy that consists of cisplatin, fluorouracil, and methotrexate can be effective. 14 Thus, the management of SCC and IPSCC actually merges into one treatment pathway, despite their different clinical presentations and distinct histology. The evidence for this is not well established in the literature, which includes reviews that looked at outcomes of SCC and IPSCC separately or that considered the entities together but not comparatively. [15] [16] [17] The paucity of literature on the characteristics and behavior of these two different forms of SCC is likely due to the relative rarity of these entities. The purpose of this study was to present, to our knowledge, the first multi-institutional comparative analysis of outcomes of patients with sinonasal SCC and IPSCC.
METHODS
After obtaining institutional review board approval at both institutions, the pathology data bases at the Cleveland Clinic Foundation and Indiana University were queried, from January 1995 to December 2015, for patients with sinonasal SCC. Patient data was de-identified, and the patients were subdivided into those with and without associated IP. Demographic, pathologic, and radiographic tumor characteristics were extracted from the records as well as treatments and outcomes. Once collected, these data were initially compared between SCC and IPSCC, with further analysis performed that compared low-stage (T1 or T2) and high-stage (T3 and T4) disease. When a characteristic could not be determined from the patient chart, it was noted as unknown, with statistical analysis only performed on identifiable data points. Data analysis was performed by using Microsoft Excel (Microsoft Corp, Redmond, WA) and GraphPad (Graphpad Software Inc., La Jolla, CA). Kaplan-Meier curves were obtained by using SPSS (IBM, Corp., Armonk, NY). Significance within analyses was based on a p value of Ͻ0.05.
RESULTS

Demographic Data
The pooled data comprised 117 patients with sinonasal SCC: 88 with SCC, 29 with IPSCC. Demographic data are detailed in Table 1 . The mean age at diagnosis was similar in both SCC and IPSCC groups (63 versus 64 years, respectively), as was the proportion of female patients (36 versus 34%, respectively; p Ͼ 0.99). Smokers represented 64% (SCC) and 55% (IP) (p ϭ 0.30); excessive alcohol intake was noted in 16% of patients with SCC and 21% of patients with IPSCC (p ϭ 0.56).
Pathologic and Radiologic Characteristics
Pathologic and radiologic characteristics are detailed in Table 2 . The majority of IPSCC were moderately differentiated, whereas moderately and poorly differentiated cancers were represented evenly in SCC. Although T4a disease occurred more commonly among patients with SCC, no significant difference was noted when high-and low-stage cancers were compared. Nodal metastasis was more likely in patients with SCC (18 versus 0%; p Ͻ 0.02). No difference was seen in lymphovascular invasion (LVI), with a minority of patients with SCC (15%) and patients with IPSCC (10%) who demonstrated this feature. Perineural invasion (PNI) was also seen only in a minority of patients (11 and 3%, respectively), with no significant difference noted when patients with SCC and patients with IPSCC were compared (p ϭ 0.18). Of note, these pathologic findings were not always available. Both LVI and PNI had approximately one-fourth of patients excluded from analysis due to a lack of this diagnostic information, with 30 patients with SCC and 35 patients with IPSCC excluded from this analysis. The maxillary sinus was the most commonly involved subsite, followed by the nasal cavity (51%, 35% SCC versus 45%, 38% IPSCC, respectively). Frontal, ethmoid, and sphenoid sinuses contained primary tumors only in patients with SCC.
Treatment and Outcomes
Upfront treatment consisted of surgery in 84% of patients with SCC and 97% of patients with IPSCC (p ϭ 0.18), and 68 and 55% of patients received radiation (p ϭ 0.19), and 25 and 21% received chemotherapy. 
High-and Low-Stage Disease
Analysis was performed after the data were subdivided into high (T3 and T4) and low (T1 and T2) stage disease. When examining outcomes based on high-and low-stage disease, significance was achieved only for nodal metastasis, which was greater in high-stage SCC than for high-stage IPSCC (p ϭ 0.03). No difference was noted in overall or disease-free survival between high and low stages.
High-and Low-Grade Disease
A comparison was also made among all data for which tumor grade was available. Analysis demonstrated a significant difference in overall survival but not disease-free survival for high-versus low-grade disease in all patients but not when high-grade IPSCC was compared with high-grade SCC and when low-grade IPSCC was compared with lowgrade SCC (Figs. 1-4 ). Further analysis was made to see whether PNI or LVI was skewed in high-or low-grade disease, and no significant difference was noted.
DISCUSSION
To our knowledge, this is the largest, and first multi-institutional study to directly compare demographics, treatments, and outcomes of patients with sinonasal SCC and those with IPSCC managed at two major academic centers. Although, on presentation and histologically,
Figure 1. (A) A Kaplan-Meier curve, demonstrating the overall survival (OS) for squamous cell carcinoma (SCC) versus inverted papilloma associated SCC (IPSCC). (B) A Kaplan-Meier curve, demonstrating the disease-free survival (DFS) for SCC versus IPSCC.
Figure 2. (A) A Kaplan-Meier curve, demonstrating the overall survival (OS) for high-grade squamous cell carcinoma (SCC) combined with inverted papilloma associated SCC (IPSCC). (B) A Kaplan-Meier curve, demonstrating the disease-free survival (DFS) for high-grade SCC combined with IPSCC.
these are different clinical entities, our review of the patients with sinonasal SCC and those with IPSCC demonstrated remarkable similarities with respect to demographics, location, pathologic characteristics, treatment, and outcomes. Karligkiotis et al., 16 noted in their review of patients with IPSCC that high grade but not high stage was a negative prognostic factor, and Rawal et al. 15 noted the same finding in their review of patients with SCC. In our study, we also found that high grade was a negative prognostic factor for overall survival but did not note any significant difference when patients with IPSCC and those with SCC were compared in high and low grades. Similarly, we did not note any difference in disease-free survival. A limitation of our subgrouping of patients into high-and low-stage disease was the decrease in the number of patients, especially in the IPSCC group, which may have affected finding statistical significance. Further analysis of high-versus low-grade tumors did not demonstrate any difference in LVI or PNI, which suggested that the tumor biology that led to decreased survival was not related to these typically defined characteristics of aggressiveness. When the two disease subsets were subdivided for high and low stage, it was noted that there was a higher propensity for lymph node metastasis in patients with high-stage SCC. No difference, however, was noted for distant metastasis. In a review of Ͼ2500 patients with sinonasal SCC in the Surveillance, Epidemiology, and End Results (SEER) data base, Ansa et al. 2 found a rate of nodal disease of ϳ60%, higher than the 18% seen overall in our study. A large review by Liang et al. 4 of 86 patients with IPSCC found a rate of ϳ6% nodal disease. Of note, neither of these studies stratified lymph node status based on tumor stage or grade. The increased propensity for nodal metastasis in high-stage SCC may suggest a more aggressive underlying tumor biology than in IPSCC. However, there was no significant increase in PNI or LVI noted in our results. The significance of this finding remains unclear but does suggest that more research is needed to determine risk factors and features for progression, e.g., molecular signaling pathways. [18] [19] [20] Results of previous studies indicated that IP may be related to smoking. 5, 8 In our analysis, no greater smoking association was seen in the IPSCC group across disease-stage subgroups. although our study was able to differentiate smokers and nonsmokers, we were unable to stratify by pack years due to limitations in data availability. It is also important to note that this lack of difference between patients with SCC and patients with IPSCC with respect to smoking status may also be due to the increased malignancy risk with smoking seen, irrespective of tumor biology.
The main limitation of this study was that, because it was multiinstitutional, a number of surgeons were involved in caring for these patients and thus there likely were variances in surgical techniques between the institutions, which may account for some of the differences noted. Although not a limitation, we also could not comment on HPV status, either directly or indirectly via P16. Although there is some indication that HPV is associated with IPSCC and IP with severe dysplasia, 9 overall, the evidence has been contradictory. Based on available evidence, including the results from this comparative multi-institutional analysis, SCC and IPSCC seemed to be similar disease entities. Current treatment paradigms for SCC with and without IP association seemed appropriate, given our findings that outcomes of these diseases were similar. However, our findings did uncover that, although outcomes from the management of these entities were indeed similar, there may be subtle differences in the behavior of SCC and IPSCC with respect to their propensity for nodal metastasis, which warrants further investigation.
CONCLUSION
Although sinonasal SCC and IPSCC are often considered different diseases, their demographics, pathologic characteristics, treatment, and outcomes appear similar. Advanced-stage SCC seems to exhibit an increased propensity for nodal metastasis, which may indicate a more aggressive underlying tumor biology, and high-grade disease regardless of the association with IP has decreased overall survival. 
